Dr. Po-Chang Thomas Chiang
My Social Links

Dr. Po-Chang Thomas Chiang

Senior Scientist
Genentech/Roche, USA

Highest Degree
Ph.D. in Analytical Chemistry from Western Michigan University, USA

Share this Profile

Area of Interest:

Biomedical Sciences
100%
Pharmaceutics
62%
Drug Absorption
90%
Chromatography
75%
Instrumentation
55%

Research Publications in Numbers

Books
0
Chapters
1
Articles
51
Abstracts
0

Selected Publications

  1. Chiang, P.C., J.D. Warner and D. Tung, 2016. The spatial response of penh as a secondary readout for the airway hyper-reactivity in three different rodent models of airway inflammation: A pilot comparison study. Br. J. Applied Sci. Technol., 13: 1-10.
  2. Chiang, P.C., D. Sutherlin, J. Pang and L. Salphati, 2016. Investigation of dose-dependent factors limiting oral bioavailability: Case study with the PI3K-δ inhibitor. J. Pharm. Sci., 105: 1802-1809.
    CrossRef  |  Direct Link  |  
  3. Chou, K.J., L. Bao, K.R. Kam, C. Gu and P.C. Chaing, 2015. Evaluation of nanoparticle formation feasibility upon wet milling based on physicochemical properties of drug molecules. Lett. Applied NanoBioSci., 4: 231-235.
  4. Chiang, P.C., K.R. Kam and K.J. Chou, 2015. Investigation of intrinsic dissolution rate based absorption model to predict exposure enhancement via nanosuspension formulation of 1, 3-dicyclohexylurea in rats. Lett. Applied NanoBioSci., 4: 241-246.
  5. Chiang, P.C., Y. Shi and Y. Cui, 2014. Temperature dependence of the complexation mechanism of celecoxib and hydroxyl-β-cyclodextrin in aqueous solution. Pharmaceutics, 6: 467-480.
    CrossRef  |  Direct Link  |  
  6. Chiang, P.C., S. Gould, M. Nannini, A. Qin and Y. Deng et al., 2014. Nanosuspension delivery of paclitaxel to xenograft mice can alter drug disposition and anti-tumor activity. Nanoscale Res. Lett., Vol. 9. 10.1186/1556-276X-9-156.
    CrossRef  |  
  7. Daniels, J.S., Y. Lai, S. South, P.C. Chiang and D. Walker et al., 2013. Inhibition of hepatobiliary transporters by a novel kinase inhibitor contributes to hepatotoxicity in beagle dog. Drug Metab. Lett., .
    PubMed  |  Direct Link  |  
  8. Cui, Y., P.C. Chiang, E.F. Choo, J. Boggs and J. Rudolph et al., 2013. Systemic in vitro and in vivo evaluation for determining the feasibility of making an amorphous solid dispersion of a B-Raf (rapidly accelerated fibrosarcoma) inhibitor. Int. J. Pharm., 454: 241-248.
    CrossRef  |  Direct Link  |  
  9. Chiang, P.C., Y. Cui, J. Lubach, Y. Ran and K.J. Chou et al., 2013. In vitro and in vivo evaluation of amorphous solid dispersions generated by different bench-scale processes, using griseofulvin as a model compound. AAPS J., 2: 608-617.
    CrossRef  |  Direct Link  |  
  10. Chiang, P.C., H. La, H. Zhang and H. Wong, 2013. Systemic concentrations can limit the oral absorption of poorly soluble drugs: An investigation of non-sink permeation using physiologically based pharmacokinetic modeling. Mol. Pharm., 10: 3980-3988.
    CrossRef  |  Direct Link  |  
  11. Chiang, P.C. and H. Wong, 2013. Incorporation of physiologically based pharmacokinetic modeling in the evaluation of solubility requirements for the salt selection process: A case study using phenytoin. AAPS J., 15: 1109-1118.
    CrossRef  |  Direct Link  |  
  12. Chiang, P.C., Y. Deng, S. Ubhayaka, H. La and Y. Cui et al., 2012. Novel nanoparticles formulation for cassette dosing via intravenous injection in rats for high throughput pharmacokinetic screening and potential applications. J. Nanosci. Nanotechnol., 12: 7993-8000.
    CrossRef  |  
  13. Chiang, P.C., K.J. Chou, Y. Cui, A. Sambrone, C. Chan, R. Hart and Y. Ran, 2012. Evaluation of spray-dried drug load and polymer by using a 96-well plate vacuum dry system for amorphous solid dispersion drug delivery. AAPS Pharm. Sci. Tech., 13: 713-722.
    CrossRef  |  
  14. Selbo, J.G. and P.C. Chiang, 2011. Absorption and Physicochemical Properties of the NCE. In: ADMET for Medicinal Chemists: A Practical Guide, Tsaioun, K. and S.A. Kates (Eds.). Chapt. 3, John Wiley and Sons, Inc., New York.
  15. Chiang, P.C., Y.Q. Ran, K.J. Chou, Y. Cui and H. Wong, 2011. Investigation of utilization of nanosuspension formulation to enhance exposure of 1, 3-Dicyclohexylurea in rats: preparation for PK/PD study via subcutaneous route of nanosuspension drug delivery. Nanoscale Res. Lett., 6: 413-413.
    CrossRef  |  
  16. Chiang, P.C., S.A. South and S.P. Wene, 2011. The impact of dosing interval in a novel tandem oral dosing strategy: Enhancing the exposure of low solubility drug candidates in a pre-clinical setting. J. Drug Deliv., Volume 2011. 10.1155/2011/528284.
    CrossRef  |  
  17. Chiang, P.C., D.C. Thompson, S. Ghosh and M.R. Heitmeier, 2011. A formulation-enabled pre-clinical efficacy assessment of a farnesoid X receptor (FXR) agonist, GW4064, in hamsters and cynomolgous monkeys. J. Pharm. Sci., 100: 4722-4733.
    PubMed  |  Direct Link  |  
  18. Chiang, P.C., Y. Hu, J.D. Blom and D.C. Thompson, 2010. Evaluating the suitability of using rat models for preclinical efficacy and side effects with inhaled corticosteroids nanosuspension formulations. Nanoscale. Res. Lett., 5: 1010-1019.
    CrossRef  |  Direct Link  |  
  19. Chiang, P.C., S.A. South, K.A. Foster, J.S. Daniels, S.P. Wene, L.A. Albin and D.C. Thompson, 2010. Utilization a novel tandem oral dosing strategy to enhance exposure of low solubility drug candidates in pre-clinical setting. J. Pharm. Sci., 99: 3132-3140.
  20. Chiang, P.C., N.N. Kishore and D.C. Thompson, 2010. Combined use of pharmacokinetic modeling and a steady-state delivery approach allows early assessment of IκB kinase-2 (IKK-2) target safety and efficacy approach allows early assessment of IκB kinase-2 (IKK-2) target safety and efficacy. J. Pharm. Sci., 99: 1278-1287.
    CrossRef  |  
  21. Sommers, C.D., J.M. Thompson, J.A. Guzova, S.L. Bonar and R.K. Rader et al., 2009. Novel tight binding inhibitory factor- κB kinase inhibitors (IKK-2) demonstrate target specific anti-inflammatory activities in cellular assays and following oraland local delivery in an in vivo model of airway inflammation. J. Pharm. Exp. Thera., 330: 377-388.
    CrossRef  |  
  22. Schoell, A.R., B.R. Heyde, D.E. Weir, P.C. Chiang, Y. Hu and D.K. Tung, 2009. The development of a novel euthanasia method for mice in support of rapid time course pulmonary pharmacokinetic studies. J. Am. Assoc. Lab. Anim. Sci., 48: 506-511.
    Direct Link  |  
  23. Mbalaviele, G., C.D. Sommers, S.L. Bonar, S. Mathialagan and J.F. Schindler et al., 2009. A novel, highly selective, tight binding IkappaB kinase-2 (IKK-2) inhibitor: a tool to correlate IKK-2 activity to the fate and functions of the components of the nuclear factor-kappaB pathway in arthritis-relevant cells and animal models. J. Pharm. Exp. Thera., 329: 14-25.
    CrossRef  |  PubMed  |  
  24. Chiang, P.C., Y. Hu, A. Thurston, C.D. Sommers and J.A. Guzova et al., 2009. Pharmacokinetic and pharmacodynamic evaluation of the suitability of using fluticasone and an acute rat lung inflammation model to differentiate lung versus systemic efficacy. J. Pharm. Sci., 98: 4354-43614.
    CrossRef  |  Direct Link  |  
  25. Chiang, P.C., S.A. South, J.S. Daniels, D.R. Anderson and S.P. Wene et al., 2009. Aqueous versus non-aqueous salt delivery strategies to enhance oral bioavailability of a mitogen-activated protein kinase-activated protein kinase (MK-2) inhibitor in rats. J. Pharm. Sci., 98: 248-456.
    CrossRef  |  Direct Link  |  
  26. Chiang, P.C., J.W. Alsup, Y. Lai, Hu, Y. Heyde, R. Bruce and D. Tung, 2009. Evaluation of Aerosol delivery of nanosuspension for pre-clinical pulmonary drug delivery. Nanoscale Res. Lett., 4: 254-261.
    CrossRef  |  
  27. Chiang, P.C. and Y. Hu, 2009. Simultaneous determination of LogD, LogP and pKa of drugs by using a 96-well plate RP HPLC and its in vivo correlation. J. Combinatorial Chem. High Throughput Screening, 12: 250-257.
  28. Yang, J.Z., A.L. Young, P.C. Chiang, A. Thurston and D.K. Pretzer, 2008. Fluticasone and budesonide nanosuspensions for pulmonary delivery: Preparation, characterization and pharmacokinetic studies. J. Pharm. Sci., 97: 4869-4878.
    CrossRef  |  PubMed  |  
  29. Lai, Y., P.C. Chiang, J.D Blom, N. Li and K. Shevlin et al., 2008. Comparison of in vitro nanoparticles uptake in various cell lines and in vivo pulmonary cellular transport in intratracheally dosed rat model. Nanoscale Res. Lett., 3: 321-329.
    CrossRef  |  
  30. Ghosh, S., P.C. Chiang, J.L. Wahlstrom, H. Fujiwara, J.G. Selbo and S.L. Roberds, 2008. Oral delivery of 1,3-dicyclohexylurea nanosuspension enhances exposure and lowers blood pressure in hypertensive rats. Basic Clin. Pharmacol. Toxicol., 125: 453-458.
    CrossRef  |  PubMed  |  
  31. Chiang, P.C. and J.C. Means, 2008. Quantification of benzo[a]pyrene-guanine adducts in in vitro samples by LC tandem mass spectrometry with stable isotope internal standardization. J. Liquid Chromatography Related Technol., 31: 3169-3193.
    CrossRef  |  
  32. Wahlstrom, J.L., P.C. Chiang, S. Ghosh, C.J. Warren and S.P. Wene et al., 2007. Pharmacokinetic evaluation of a N,N'-dicyclohexylurea nanosuspension formulation to support early efficacy assessment. Nanoscale. Res. Lett., 2: 291-296.
  33. Chiang, P.C., J.L. Wahlstrom, J.G. Selbo, S. Zhou and S.P. Wene et al., 2007. 1,3 dicyclohexyl urea nanosuspension for intravenous steady-state delivery in rat. J. Exp. Nanosci., 2: 239-250.
    CrossRef  |  
  34. Chiang, P.C., K.A. Foster, M.C. Whittle, C.C. Su and D.K. Pretzer, 2006. Medium throughput pK a determinations of drugs and chemicals by reverse phase HPLC with an organic gradient. J. Liquid Chromatography Related Technol., 29: 2291-2301.
    CrossRef  |  
  35. Chiang, P.C., C.C. Su, K. Block and D. Pretzer, 2005. Medium throughput pK a determination of drugs and chemicals using an HPLC equipped with a DAD as a flow injection apparatus. J. Liquid Chromatography Related Technol., 28: 3035-3043.
    CrossRef  |